Hansa Biopharma — Januar 2024
-
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
-
Det ser da rigtigt fint ud. Ok salg, går fint med indrullering til både Post Approval study og ConfIdes og måske lidt bedre end ventet til Anti-GBM. Der er nu gang Genterapi Duchenne studiet og der en del info og uddybning af Hansa 5487 i præsentationen.
-
Hansa Biopharma preliminary Q4: Imlifidase records a very healthy improvement during Q4 after a quarter with low activity
-
Sarepta Therapeutics lukkede oppe +16% i går i US.
"FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy"
https://www.statnews.com/2024/01/09/fda-peter-marks-full-approval-sarepta-duchenne-gene-therapy/
Selvom "virker tilbøjelig" ikke bekræfter direkte, så antyder det ... så måske positiv afsmitning på Hansa Biopharma i et ellers nok rødt marked i dag onsdag.
-
Kort video...Hansa Biopharma, som har været et smertens barn, er kommet i gang med salget af et stof til nyretransplantation, og det har markedet taget godt imod.
https://www.proinvestor.com/boards/117934
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind